Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor–Positive Breast Cancer

Peter Schmid(Queen Mary University of London), Alastair M. Thompson(Baylor College of Medicine)

Journal of Clinical Oncology

March 15, 2016

10.1200/jco.2015.63.9179

Cited by 96

Related Papers

Pembrolizumab for Early Triple-Negative Breast Cancer

|New England Journal of Medicine|2020|3.1k

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

|New England Journal of Medicine|2016|2k

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

|The Lancet|2020|1.8k

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

|The Lancet Oncology|2021|355

Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast Cancer

|New England Journal of Medicine|2024|235